^
Association details:
| Biomarker: | MPRIP-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC
Published date:
07/01/2019
Excerpt:
A 27-year-old Chinese female...identified a novel MPRIP-ALK fusion which was confirmed by reverse transcriptase–PCR, Sanger sequencing, and break-apart FISH probe assay and immunohistochemistry (ALK D5F3 antibody)...The patient commenced on crizotinib (250 mg, twice daily) as second-line treatment...Partial response was further confirmed after 3 months (Fig. 2C). The patient remains on crizotinib treatment at data cutoff (February 22, 2019), yielding a progression-free survival of at least 11 months.
DOI:
https://doi.org/10.1016/j.jtho.2019.02.030
